IPP Bureau
Roche gets USFDA approval of Xofluza to treat influenza in children
By IPP Bureau - August 13, 2022
Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of age
AstraZeneca completes acquisition of TeneoTwo
By IPP Bureau - August 13, 2022
AstraZeneca has acquired all outstanding equity of TeneoTwo in exchange for an upfront payment of $100m.
Enhertu approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
By IPP Bureau - August 13, 2022
Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease
Pfizer announces positive results from Phase 3 study of 20-valent pneumococcal conjugate vaccine
By IPP Bureau - August 13, 2022
Pfizer plans to submit an sBLA by the end of this year, subject to discussions with U.S. FDA
Regen BioPharma develops novel dedifferentiation approach for increasing efficacy of CAR-T Cells to treat solid tumors
By IPP Bureau - August 13, 2022
Company creates Younger T Cells for fighting cancer using its NR2F6 technology
Tetra Bio-Pharma secures $6,000,000 financing from Alpha Blue Ocean
By IPP Bureau - August 13, 2022
Congenica announces partnership with Avesthagen
By IPP Bureau - August 13, 2022
New deal strengthens Congenica’s presence in India
MoU signed between Ministry of Ayush and MeitY
By IPP Bureau - August 13, 2022
MeitY will provide technical support for digitalisation of the Ayush Sector under the Ayush Grid project for a period of three years
We must be careful in adopting global technological practices, says Union Health Secretary
By IPP Bureau - August 13, 2022
Urged stakeholders to come up with similar digital platforms and create homegrown best practices where Indian methods and Indian solutions dominate the digital spaces
GL Chemtech partners with Edgewater Capital to accelerate growth
By IPP Bureau - August 12, 2022
Investment in response to increased demand for North American-based chemistry services
Hikal shows 17% degrowth in Q1 FY23
By IPP Bureau - August 12, 2022
Pharmaceutical sales de-grew 18% YoY and stood at Rs. 224 crore whereas Crop Protection sales de-grew by 15% at Rs. 154 crore
IOL Chemicals and Pharmaceuticals reports Q1 FY23 revenue of Rs. 570.2 Cr
By IPP Bureau - August 12, 2022
The company will strengthen its position in the ‘green solvent’ market by increasing its capacity by 20% to 120,000 MTPA from 100,000 MTPA before the end of current fiscal
Apollo Hospitals posts Q1 FY23 consolidated PAT at Rs. 317.11 Cr
By IPP Bureau - August 12, 2022
Apollo Hospital Group completed the acquisition of a hospital asset in Gurugram for a consideration of around Rs 450 crore.
ShilpaMedicare Q1FY23 consolidated PAT drops to to Rs. 84.85 lakhs
By IPP Bureau - August 12, 2022
Kaléo announces appointments and new government business unit
By IPP Bureau - August 12, 2022
